FOR IMMEDIATE RELEASE	Press Contact:	Michael Tew
		Alexandra Preate
		CapitalHQ
		(212) 588-9148
		(917) 669-7473 cell
		mtew@capitalhq.com
		apreate@capitalhq.com

Duravest Signs Engagement With RSM McGladrey to Move Forward on its Subsidiary Valuation Requirements

Duravest takes further steps towards becoming current in its SEC filings

CHICAGO, IL--(MARKET WIRE)--Jun 27, 2006--Duravest, Inc. (OTC: DUVT.PK) (XETRA: DUV.DE), a unique company that is leading the way in strategically acquiring, developing, and accelerating next-generation convergent medical technology firms, has signed an engagement today with the accounting firm RSM McGladrey in order to provide value calculations of certain intangibles of its Estracure subsidiary. The move is another step in the company’s progress in becoming current in its SEC filings.

RSM McGladrey has been hired by Duravest specifically to provide value calculations of certain intangible assets to be used in assisting management in complying with the requirements of SFAS 141 (Statement of Financial Accounting Standard), Business Combinations. RSM McGladrey, Inc. with offices in 22 states (and as part of an international network encompassing 70 countries) is a leading business consulting, accounting, and tax firm that focuses on mid-sized companies.

Dr. Ogan Gurel, Duravest CEO, noted, “We are very pleased to be working with RSM McGladrey going forward on this important project, which is a significant component of Duravest’s efforts to become up-to-date with its SEC requirements.”

Duravest, Inc.

Duravest, Inc. (OTC: DUVT.PK) (XETRA: DUV.DE) is a publicly traded holding company that initiates and develops strategic investments in next-generation convergent medical technologies. Duravest currently has two subsidiaries: Estracure, Inc. - based in Montreal, Canada - which is developing a next-generation coronary stent based on proprietary 17-beta-estradiol and PST, GmbH - based in Munich, Germany - which currently markets patented bio-magnetic therapies for a number of orthopedic conditions and their associated pain management. Estracure is developing a next-generation stent that specifically addresses potential safety issues with the current generation of coronary drug-eluting stents and thus represents not just a potential niche player but a replacement product in the market. The active agent in the Estracure stent - 17-beta-estradiol - has a pro-healing effect (by stimulating re-endothelialization) that has been documented by extensive in vitro and in vivo studies.

####

Safe Harbor Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward-looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.